• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    CG Oncology, Inc. - Common stock (NQ: CGON )

    36.66 +1.25 (+3.53%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 388,422
    Open 35.92
    Bid (Size) 34.50 (1)
    Ask (Size) 39.40 (1)
    Prev. Close 35.41
    Today's Range 34.96 - 37.98
    52wk Range 25.77 - 50.23
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Closer Look at 9 Analyst Recommendations For CG Oncology
    Via Benzinga
    CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
    - First Patient Dosed in Expanded Access Program and Enrollment Ongoing - 
    From CG Oncology Inc.
    Via GlobeNewswire

    Performance

    YTD
    -7.54%
    -7.54%
    1 Month
    +8.69%
    +8.69%
    3 Month
    -2.60%
    -2.60%
    6 Month
    -7.54%
    -7.54%
    1 Year
    -7.54%
    -7.54%

    More News

    Read More
    CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
    From CG Oncology Inc.
    Via GlobeNewswire
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Decoding 10 Analyst Evaluations For CG Oncology
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
    From CG Oncology Inc.
    Via GlobeNewswire
    CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
    Via InvestorPlace
    CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    From CG Oncology Inc.
    Via GlobeNewswire
    Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
    From CG Oncology Inc.
    Via GlobeNewswire
    CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
    From CG Oncology Inc.
    Via GlobeNewswire
    IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline?
    Via Investor's Business Daily
    Topics Initial Public Offering
    Exposures Securities Market
    CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
    From CG Oncology Inc.
    Via GlobeNewswire
    CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
    From CG Oncology Inc.
    Via GlobeNewswire
    Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
    Via The Motley Fool
    Topics Initial Public Offering
    Exposures Securities Market
    3 attractive stocks that insiders are buying
    Via MarketBeat
    CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From CG Oncology, Inc.
    Via Business Wire
    KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.